ERA-CVD Joint Transnational Call 2019
Basic Information
Cardiovascular diseases (CVD) are the largest cause of death in the European Union (EU), as they account for around 2 million deaths per year. Furthermore, these diseases are one of the leading causes of long-term sickness; chronic diseases and labour force loss due to disability and thus pose a major health-and socio-economic problem in Europe and beyond. Based on a better understanding of the causes of CVD, development of new innovative medicinal products and improvement in medical technology requires innovative research based on scientific excellence. Cardiovascular research and its translation into better preventive, diagnostic and therapeutic outcomes are fundamental for patients in Europe and worldwide.
| Network | ERA-CVD | ||||||
| Website | https://www.era-cvd.eu/388.php | ||||||
| Aim of the joint call | The ERA-CVD funding organizations particularly wish to promote multi-disciplinary work and translational research proposals. The individual components of joint applications should be complementary and contain novel, ambitious ideas to answer key questions or lead to a step-wise change in understanding of cardiovascular diseases. There should be a clear added value in funding the collaboration over individual projects by sharing of resources (models, databases, diagnosis etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies. Hence, JTC2019aims at enabling Early Career Scientists in different countries to build effective collaborations and interchange on common multidisciplinary research projects, hence establish new consortia in cardiovascular disease. The opportunity to independently develop and perform highly innovative research projects enables capacity building and empowering of Early Career Scientists. | ||||||
| Type of joint call | One Stage - Call with no pre-proposals submission | ||||||
| Events |
|
||||||
| Is call co-funded? | No | ||||||
| Call follow up funding | n/a | ||||||
| Call reasons | n/a | ||||||
| Research fields |
|
||||||
| Type of research | n/a | ||||||
| Target groups |
|
||||||
| Participating networks | n/a |
Organisations Participating
Funded Projects
| Acronym | Title | Start | End | No. partners |
|---|---|---|---|---|
| B-eatATHERO | “The role of B cell immunity in accelerated atherosclerosis” | 01/05/2020 | 30/04/2023 | 3 |
| CHEMICAL | “Cancer Therapy-Related Clonal Hematopoiesis as a Driver of ... | 01/05/2020 | 30/04/2023 | 3 |
| DEFIANCE | “Defining Environmental Factors Influencing and Affecting Ne... | 01/05/2020 | 30/04/2023 | 3 |
| FIBRONETx | “Casting NETs in the fibrotic heart” | 01/05/2020 | 30/04/2023 | 3 |
| Gut-brain-immune-HHD | “Gut-brain interactions modulate immune response in Hyperten... | 01/05/2020 | 30/04/2023 | 4 |
| HF-MetaB | “Metabolic therapy of heart failure: which role for B vitami... | 01/05/2020 | 30/04/2023 | 4 |
| IMPHLeXIONS | “Inflammation and Metabolism in Pulmonary Hypertension are L... | 01/05/2020 | 30/04/2023 | 3 |
| MEIDIC-VTACH | “Electro-Imaging for the preDICtion of Ventricular TACHyarrh... | 01/05/2020 | 30/04/2023 | 3 |
| MyPenPath | “The Role of the Pentose Phosphate Pathway on Myeloid Cell A... | 01/05/2020 | 30/04/2023 | 4 |
| SCALE | “Single Cardiomyocyte ALlelic imbalancE in hypertrophic card... | 01/05/2020 | 30/04/2023 | 4 |
| SICVALVES | “Multiscale modeling of Valvular Heart Diseases. Understandi... | 01/05/2020 | 30/04/2023 | 3 |